# Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer

> **NCT00040807** · PHASE2 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group**

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00040807
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11-19
- **Primary completion:** 2005-04
- **Final completion:** 2009-05-01
- **Target enrollment:** — (—)
- **Last updated:** 2023-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040807, "Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00040807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*